標(biāo)題: Titlebook: Gene Therapy; Principles and Appli Thomas Blankenstein Book 1999 Birkh?user Verlag 1999 DNA.HIV.bacteria.biotechnology.cancer.gene expressi [打印本頁] 作者: 惡化 時(shí)間: 2025-3-21 19:25
書目名稱Gene Therapy影響因子(影響力)
書目名稱Gene Therapy影響因子(影響力)學(xué)科排名
書目名稱Gene Therapy網(wǎng)絡(luò)公開度
書目名稱Gene Therapy網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Gene Therapy被引頻次
書目名稱Gene Therapy被引頻次學(xué)科排名
書目名稱Gene Therapy年度引用
書目名稱Gene Therapy年度引用學(xué)科排名
書目名稱Gene Therapy讀者反饋
書目名稱Gene Therapy讀者反饋學(xué)科排名
作者: 大火 時(shí)間: 2025-3-21 21:29 作者: Endoscope 時(shí)間: 2025-3-22 02:42 作者: Criteria 時(shí)間: 2025-3-22 05:25
https://doi.org/10.1007/978-3-030-27621-8t is likely that modifications of both the vector and packaging lines should result in even higher titer, targetable viruses with elevated and/or regulated gene expression. Thus, it is likely that retroviral vectors will continue to be the vector of choice for many gene therapy applications.作者: temperate 時(shí)間: 2025-3-22 09:10
Staatsbürgerrechte und soziale Klassen 1996]. After in-fection, the Ad vector expresses the transgene in the nucleus of replicating and non-replicating cells in an epi-chromosomal fashion, where the duration of gene expres-sion is transient over time [Rosenfeld et al., 1991; Kass-Eissler et al., 1994; Smith et al., 1993; Engelhard et al., 1994; Yang et al., 1994a, b].作者: synovial-joint 時(shí)間: 2025-3-22 16:39 作者: synovial-joint 時(shí)間: 2025-3-22 18:33 作者: 四目在模仿 時(shí)間: 2025-3-23 01:07 作者: incisive 時(shí)間: 2025-3-23 03:26
Gene Transfection Using Particle Bombardmentwith transfection efficiencies of 1–15%. In this article, we summarize the characteristics of this approach, present our preliminary results and discuss possible future application of this gene transfer technology.作者: 不怕任性 時(shí)間: 2025-3-23 08:52 作者: 誘騙 時(shí)間: 2025-3-23 11:40
Retroviral Vectorst is likely that modifications of both the vector and packaging lines should result in even higher titer, targetable viruses with elevated and/or regulated gene expression. Thus, it is likely that retroviral vectors will continue to be the vector of choice for many gene therapy applications.作者: inflame 時(shí)間: 2025-3-23 16:55
Adenovirus Vectors for Gene Therapy 1996]. After in-fection, the Ad vector expresses the transgene in the nucleus of replicating and non-replicating cells in an epi-chromosomal fashion, where the duration of gene expres-sion is transient over time [Rosenfeld et al., 1991; Kass-Eissler et al., 1994; Smith et al., 1993; Engelhard et al., 1994; Yang et al., 1994a, b].作者: 鋼筆尖 時(shí)間: 2025-3-23 20:36 作者: Anguish 時(shí)間: 2025-3-24 00:29
https://doi.org/10.1007/978-981-99-8699-6plification, mutation, translocation leading to structural alteration, or change in transcriptional regulation might either lead to, or be associated with, induction of a malignant phenotype in the cell where these changes occurred [13–15].作者: doxazosin 時(shí)間: 2025-3-24 05:07 作者: mutineer 時(shí)間: 2025-3-24 09:40
The c-myb Protooncogene: A Novel Target for Human Gene Therapyplification, mutation, translocation leading to structural alteration, or change in transcriptional regulation might either lead to, or be associated with, induction of a malignant phenotype in the cell where these changes occurred [13–15].作者: hardheaded 時(shí)間: 2025-3-24 10:49 作者: Interferons 時(shí)間: 2025-3-24 15:37 作者: amnesia 時(shí)間: 2025-3-24 23:02
https://doi.org/10.1007/978-3-319-60237-0 likely to have farreaching consequences in the practice of medicine, as we enter the next millennium. Currently, there are over 200 seperate active clinical trials with over 2,500 patients entered. These studies involve over 20 countries and include patients with a wide range of diseases, including作者: engrave 時(shí)間: 2025-3-25 02:37
https://doi.org/10.1007/978-3-030-27621-8diseases, from cancer to virus infection to arthritis. Although the current vectors have worked efficiently for gene transfer in the initial trials, it is likely that modifications of both the vector and packaging lines should result in even higher titer, targetable viruses with elevated and/or regu作者: novelty 時(shí)間: 2025-3-25 04:25
Staatsbürgerrechte und soziale Klassen efficient at transferring genes to a wide variety of target cells . and . and at ex-pressing exogenous genes at a high level [Crystal, 1995; Horwitz, 1996]. After in-fection, the Ad vector expresses the transgene in the nucleus of replicating and non-replicating cells in an epi-chromosomal fashion,作者: evasive 時(shí)間: 2025-3-25 07:39
Nicole Stokes-DuPass,Ramona Frujaer formulations [1–3], although not reaching the efficiencies of viral vectors, have been introduced already into clinical . gene therapies. Nonviral systems are attractive for the following reasons: (i) they may be very flexible with respect to the size of DNA to be transported; (ii) in contrast to作者: 施舍 時(shí)間: 2025-3-25 12:47 作者: Odyssey 時(shí)間: 2025-3-25 16:48 作者: 使無效 時(shí)間: 2025-3-25 20:08
Nasreen Chowdhory,Biswajit Mohantye techniques, particle-mediated gene transfer (PMT) or “gene gun” has been developed and promising results have been reported in the last few years. Other approaches include use of naked DNA injection (particlularly into muscle), protein coupled DNA to target cellular receptors, calcium phosphate tr作者: CLASH 時(shí)間: 2025-3-26 02:14 作者: Extricate 時(shí)間: 2025-3-26 07:44 作者: 摘要記錄 時(shí)間: 2025-3-26 09:43 作者: 衣服 時(shí)間: 2025-3-26 16:06 作者: 墻壁 時(shí)間: 2025-3-26 17:12 作者: indubitable 時(shí)間: 2025-3-27 00:03
Lorena Melga?o,Katharine S. Willisrking studies were the first gene transfer protocols to enter clinical practice. The principal objective of a gene marking study is to introduce, in the target cells, a gene which does not modify the function of the cells but allows them to be detected, providing information on survival, distributio作者: Debrief 時(shí)間: 2025-3-27 03:54
I lobi frontali e le loro aree principali,icularly true for hematopoietic disorders because the efficiency of gene transfer is limited and stable expression of transgenes in bone marrow has been found difficult to accomplish (Miller, 1990). In preclinical primate studies as well as in clinical trials, the percentage of hematopoietic cells e作者: 正式通知 時(shí)間: 2025-3-27 08:38
https://doi.org/10.1007/978-981-99-8699-6ransforming retro-viruses are known to carry specific genes likely to be responsible for induction of the malignant phenotype in the cells they infect [2–5]. These genes, termed viral-oncogenes (v-onc), are derived from highly conserved, normal cellular genes which were almost certainly incorporated作者: 掙扎 時(shí)間: 2025-3-27 11:35
Introduction likely to have farreaching consequences in the practice of medicine, as we enter the next millennium. Currently, there are over 200 seperate active clinical trials with over 2,500 patients entered. These studies involve over 20 countries and include patients with a wide range of diseases, including作者: Between 時(shí)間: 2025-3-27 13:54
Retroviral Vectorsdiseases, from cancer to virus infection to arthritis. Although the current vectors have worked efficiently for gene transfer in the initial trials, it is likely that modifications of both the vector and packaging lines should result in even higher titer, targetable viruses with elevated and/or regu作者: AUGUR 時(shí)間: 2025-3-27 18:32 作者: DOLT 時(shí)間: 2025-3-27 23:19 作者: FER 時(shí)間: 2025-3-28 03:58 作者: MORT 時(shí)間: 2025-3-28 09:26 作者: exhilaration 時(shí)間: 2025-3-28 11:03 作者: 傻瓜 時(shí)間: 2025-3-28 15:58
Gene Therapy for Severe Combined Immunodeficienciesoral responses [1, 2]. Affected children typically fail to thrive and become ill with recurrent infections caused by bacteria, viruses, and opportunistic pathogens. The molecular defects have now been identified for the majority of SCID phenotypes and are summarized in Table 1-1 [3–27]. The defects 作者: 會(huì)議 時(shí)間: 2025-3-28 19:54 作者: 出價(jià) 時(shí)間: 2025-3-28 23:48
Gene Therapy for Cystic Fibrosise which these studies have created in some quarters should be qualified and countered. Remarkable progress has been made and independent strategies have been tested in the very few years since the . gene was cloned. The inadequacies of the very early generation of adenoviruses were easily predicted,作者: VERT 時(shí)間: 2025-3-29 06:32 作者: AVID 時(shí)間: 2025-3-29 11:07
Gene Marking in Bone Marrow and Peripheral Blood Stem Cell Transplantationhe field, clinical studies using gene-marked bone marrow will be reviewed and discussed in the context of these controversies. Autologous bone marrow transplantation and peripheral blood cell transplantation (AuBMT and AuPBPC, respectively) are becoming an increasingly common procedure for the treat作者: obeisance 時(shí)間: 2025-3-29 13:23 作者: receptors 時(shí)間: 2025-3-29 18:46
1 Gene Transfer to Hematopoietic Cellsicularly true for hematopoietic disorders because the efficiency of gene transfer is limited and stable expression of transgenes in bone marrow has been found difficult to accomplish (Miller, 1990). In preclinical primate studies as well as in clinical trials, the percentage of hematopoietic cells e作者: COLON 時(shí)間: 2025-3-29 20:34 作者: accomplishment 時(shí)間: 2025-3-30 00:55
Liposomes in Gene Therapyation of their role deserves a detailed introduction. Therefore this article describes their preparation and role as a vehicle to deliver DNA molecules and the possible delivery mechanism of encapsulated materials.作者: 增長(zhǎng) 時(shí)間: 2025-3-30 05:03 作者: INTER 時(shí)間: 2025-3-30 11:05
Gene Therapy for Severe Combined Immunodeficienciesansfer into the stem cell of the hematopoietic system, thus allowing the appropriate expression of the normal gene into the affected cells of hematopoietic or lymphoid lineage [33–35]. However, initial difficulties in obtaining efficient transduction of stem cells have led several investigators to a作者: 全等 時(shí)間: 2025-3-30 14:00
